The complement system plays a key role in pathogen immunosurveillance and tissue
homeostasis. However, subversion of its tight regulatory control can fuel a vicious cycle of …

Spinal cord injury (SCI) is a significant cause of disability, and treatment alternatives that
generate beneficial outcomes and have no side effects are urgently needed. SCI may be …

Background Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin–
kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol …

As medicine progresses into a new era of personalised therapy, the use of monoclonal
antibodies to treat a wide range of diseases lies at the heart of this new forefront. Since the …

Background: Envenomation remains a neglected public health issue in most tropical
countries. A better understanding of the epidemiology of bites and stings by venomous …

Eculizumab has opened new horizons in the treatment of complement-mediated disorders.
Prophylactic and immunization strategies against the risk of Nesseria spp. infections are …

Tackling PPIs, particularly by stabilizing clinically favored conformations of target proteins,
with orally available, bona fide small molecules remains a significant but immensely …

While protein therapeutics are one of the most successful class of drug molecules, they are
expensive and not suited for treating chronic disorders that require long-term dosing. Adeno …

Transdermal drug delivery presents a less invasive pathway, circumventing the need to pass
through the gastrointestinal tract and liver, thereby reducing drug breakdown, initial …

There are many problems directly correlated with the systemic administration of drugs and
how they reach their target site. Targeting promises to be a hopeful strategy as an improved …